| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$277.0M | ROE | −33.27% |
| Net Margin | — | ROIC | −36.67% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline includes ERAS-0015, a pan-RAS molecular glue; ERAS-4001, a pan-KRAS inhibitor; and ERAS-12, an EGFR biparatopic antibody. The company holds license agreements with partners including Guangzhou Joyo Pharmatech, Medshine Discovery, Novartis, and NiKang Therapeutics.
| Market Cap | $5.65B | Trading Days | 1259 |
| 52W High | 24.28 |
| 52W Low | 1.33 |
| % Off High | −25.21% |
| YTD | 388.17% | 1Y | 968.24% |
| 3Y | 598.46% | 5Y | −9.20% |
| Since incept. (ann.) | 0.25% |
| Ann. Volatility (1Y) | 106.04% | Ann. Volatility (3Y) | 88.56% |
| Sharpe (1Y) | 2.84 | Sharpe (3Y) | 1.21 |
| Max Drawdown (1Y) | −59.46% | Max Drawdown (3Y) | −67.68% |
| Beta (3Y, vs SPY) | −0.48 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.55B | — |
| ORKA | Oruka Therapeutics, Inc. | $5.46B | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.94B | 48.3 |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.98B | 85.3 |
| AMRN | AMARIN CORP PLC\UK | $5.31B | — |
| TVTX | Travere Therapeutics, Inc. | $5.20B | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.27B | 105.9 |
| XENE | Xenon Pharmaceuticals Inc. | $6.28B | — |
| INDV | Indivior Pharmaceuticals, Inc. | $5.00B | 25.0 |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |
| PTCT | PTC THERAPEUTICS, INC. |
| $6.66B |
| 9.7 |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.84B | — |
